ARA-290 (also known as Cibinetide) is a synthetic 11-amino acid peptide derived from the structure of Erythropoietin (EPO). Unlike EPO, it does not stimulate red blood cell production (erythropoiesis), making it a targeted candidate for treating chronic inflammation and nerve damage without the risk of thickening the blood.

Below is a summarized report based on clinical data and research available as of 2026.

Primary Mechanism: The Innate Repair Receptor (IRR)

ARA-290 works by selectively activating the Innate Repair Receptor (IRR).

• Targeting: The IRR is a specific receptor complex (EPO receptor + CD131) that the body “turns on” during injury or extreme stress.
• Result: Activating this pathway sends a signal to the body to stop inflammatory destruction and pivot toward cytoprotection (cell protection) and regeneration.

Key Benefits & Clinical Data

Research highlights several high-impact areas where ARA-290 has shown efficacy:

A. Neuropathy and Nerve Repair

This is the most well-documented use of ARA-290.

• Small Fiber Neuropathy (SFN): Clinical trials in patients with Sarcoidosis-associated SFN showed a 40% average reduction in pain.
• Regeneration: Data suggests ARA-290 can increase corneal nerve fiber density, indicating actual regrowth of small nerve fibers rather than just masking pain.
• Diabetic Neuropathy: Studies indicate improved sensory function and reduced “burning” or “shock-like” sensations in diabetic patients.

B. Potent Anti-Inflammatory Action

• Cytokine Suppression: It significantly reduces levels of pro-inflammatory markers like TNF-alpha, IL-1β, and IL-6.
• Microglia Modulation: In the central nervous system, it suppresses the activation of microglia (immune cells in the brain), which can help reduce neuroinflammation and “brain fog.”

C. Cardiovascular and Metabolic Health

• Microvascular Support: Enhances endothelial health and microcirculation, which is vital for healing ischemic (oxygen-starved) tissues.
• HbA1c Improvement: Some trials in Type 2 Diabetes patients noted an improvement in metabolic profiles alongside nerve relief.

Data Summary Table